A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
Public ClinicalTrials.gov record NCT04459715. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study was to demonstrate superior efficacy of Xevinapant (Debio 1143) vs placebo when added to chemoradiotherapy (CRT) in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).
Study identification
- NCT ID
- NCT04459715
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 730 participants
Conditions and interventions
Conditions
Interventions
- Xevinapant (Debio 1143) Drug
- Cisplatin Drug
- Intensity Modulation Radiation Therapy (IMRT) Radiation
- Placebo Drug
Drug · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 7, 2020 (Actual)
- Primary completion
- Sep 18, 2024 (Actual)
- Completion
- Sep 18, 2024 (Actual)
- Last update posted
- Oct 8, 2025
2020 – 2024
United States locations
- U.S. sites
- 44
- U.S. states
- 24
- U.S. cities
- 36
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University of Alabama at Birmingham - Hazelrig-Salter Radiation Oncology Center (HSROC) | Birmingham | Alabama | 35233 | — |
| Banner MD Anderson Cancer Center | Gilbert | Arizona | 85234 | — |
| University of Arizona Cancer Center | Tucson | Arizona | 85724 | — |
| UC San Diego Moores Cancer Center | La Jolla | California | 92093 | — |
| Regents of the University of California | San Francisco | California | 94158 | — |
| UCSF | San Francisco | California | 94158 | — |
| The Oncology Institute of Hope & Innovation | Whittier | California | 90603 | — |
| University of Colorado at Denver and Health Sciences Center | Aurora | Colorado | 80045 | — |
| Yale Cancer Center | New Haven | Connecticut | 06519 | — |
| Lombardi Comprehensive Cancer Center, Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| ASCLEPES Research Centers | Weeki Wachee | Florida | 34607 | — |
| Columbus Regional Research Institute | Columbus | Georgia | 31904 | — |
| IACT Health, John B. Amos Cancer Center | Columbus | Georgia | 31904 | — |
| Inventa Center for Cancer Research At Fort Wayne Medical Oncology and Hematology | Fort Wayne | Indiana | 46804 | — |
| Ashland-Bellefonte Cancer Center | Ashland | Kentucky | 41101 | — |
| Norton Cancer Institute, Louisville, Kentucky, Brownsboro Hospital Campus | Louisville | Kentucky | 40241 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114-2696 | — |
| Beth Israel Deaconess (BI Lahey)/Harvard Cancer Center | Boston | Massachusetts | 02215 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University South Hospital | Ann Arbor | Michigan | 48109-9001 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Karmanos Cancer institute | Detroit | Michigan | 48302 | — |
| University of Missouri - Ellis Fischel Cancer Center | Columbia | Missouri | 65212 | — |
| MidAmerica Cancer Care | Kansas City | Missouri | 64114 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Comprehensive Cancer Center of Nevada (Southern Hills) (USA) | Las Vegas | Nevada | 89148 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89169 | — |
| NYU Langone Hospital-Long Island Oncology | Mineola | New York | 11501 | — |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone Health | New York | New York | 10016 | — |
| NYU Grossman School of Medicine | New York | New York | 10016 | — |
| Wake Forest University School of Medicine | Winston-Salem | North Carolina | 27157 | — |
| University of Cincinnati Medical Center | Cincinnati | Ohio | 45267 | — |
| University Hospital Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Ohio State University | Columbus | Ohio | 43210 | — |
| University of Oklahoma Health Sciences Center- Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| Gettysburg Cancer Center | Gettysburg | Pennsylvania | 17325 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Medical University of South Carolina- Hollings Cancer Center | Charleston | South Carolina | 29425 | — |
| MD Anderson | Houston | Texas | 77030 | — |
| IHO Corporation/Utah Cancer Specialists | Salt Lake City | Utah | 84106 | — |
| University of Virginia Medical Center | Charlottesville | Virginia | 22908 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 244 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04459715, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 8, 2025 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04459715 live on ClinicalTrials.gov.